A 52-year-old man of Indian origin presents with a 6-year history of type 2 diabetes mellitus managed with metformin 1000 mg twice daily. His current HbA1c is 8.2%. He is asymptomatic, with no polyuria or polydipsia. Physical examination reveals central obesity (waist circumference 105 cm) and acanthosis nigricans on the neck and axillae. Fasting blood glucose is 156 mg/dL, and C-peptide is 3.8 ng/mL (normal 0.8–3.1). Serum insulin is 28 mIU/mL (fasting normal <12). Anti-GAD65 antibodies are negative. What is the primary pathophysiologic mechanism driving hyperglycemia in this patient?

Explanation

## Pathophysiologic Analysis of Type 2 Diabetes **Key Point:** This patient demonstrates the hallmark pathophysiology of Type 2 diabetes mellitus (T2DM): **insulin resistance with compensatory hyperinsulinemia and relative (not absolute) insulin deficiency.** ### Diagnostic Evidence | Finding | Value | Interpretation | |---------|-------|----------------| | Duration | 6 years | Chronic T2DM (not acute presentation) | | BMI/Phenotype | Central obesity, acanthosis nigricans | Insulin resistance syndrome | | C-peptide | 3.8 ng/mL (high-normal to elevated) | **Preserved β-cell function** | | Fasting insulin | 28 mIU/mL (markedly elevated) | **Hyperinsulinemia—hallmark of insulin resistance** | | Anti-GAD65 | Negative | **Rules out autoimmune T1DM** | | HbA1c | 8.2% | Suboptimal glycemic control despite metformin | **High-Yield:** The **elevated fasting insulin (28 mIU/mL) with preserved C-peptide (3.8 ng/mL)** is the diagnostic signature of T2DM. This indicates that the pancreas is producing abundant insulin, but peripheral tissues are resistant to its action. ### The Two-Hit Hypothesis of T2DM ```mermaid flowchart TD A[Genetic predisposition + Environmental factors]:::outcome --> B[Insulin Resistance]:::outcome B --> C{Pancreatic β-cell compensation}:::decision C -->|Adequate| D[Hyperinsulinemia maintains euglycemia]:::action C -->|Inadequate| E[Relative insulin deficiency]:::outcome E --> F[Hyperglycemia develops]:::urgent F --> G[Progressive β-cell exhaustion]:::urgent G --> H[Eventual absolute insulin deficiency]:::urgent ``` ### Mechanism in This Patient 1. **Insulin Resistance** (primary defect) - Central obesity → increased visceral adiposity - Adipokine dysfunction (↓ adiponectin, ↑ TNF-α, ↑ IL-6) - Impaired glucose uptake in skeletal muscle and adipose tissue - Acanthosis nigricans is a clinical marker of severe insulin resistance 2. **Compensatory Hyperinsulinemia** - β-cells increase insulin secretion to overcome resistance - Fasting insulin 28 mIU/mL (normal <12) reflects this compensation - C-peptide remains elevated, confirming intact β-cell function 3. **Relative Insulin Deficiency** - Despite high absolute insulin levels, insulin is insufficient relative to the degree of resistance - Hyperglycemia persists (fasting glucose 156 mg/dL) despite metformin and endogenous hyperinsulinemia - This is **relative**, not absolute, deficiency (unlike T1DM) **Clinical Pearl:** Acanthosis nigricans in a diabetic patient is a clinical sign of severe insulin resistance and predicts poor glycemic control. It is associated with increased cardiovascular risk and warrants aggressive metabolic intervention. **Mnemonic:** **HOMA-IR (Homeostasis Model Assessment for Insulin Resistance):** - HOMA-IR = (Fasting Insulin × Fasting Glucose) / 405 - In this patient: (28 × 156) / 405 ≈ 10.8 (severely elevated; normal <2) - This quantifies the degree of insulin resistance. ### Why This Is NOT T1DM - **Negative anti-GAD65 antibodies** rule out autoimmune T1DM - **Elevated C-peptide and insulin** indicate preserved β-cell function - **Gradual 6-year course** is typical of T2DM, not the acute presentation of T1DM - **Central obesity and acanthosis nigricans** are features of insulin resistance, not autoimmunity [cite:Harrison 21e Ch 417]